Oppenheimer analyst Leland Gershell downgraded Soleno Therapeutics (SLNO) to Perform from Outperform without a price target after Neurocrine (NBIX) announced a deal to acquire the company for $2.9B or $53 per share in cash. The firm does not expect other bidders to emerge. Oppenheimer sees the deal closing in the current quarter given its lack of antitrust concerns.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- Neurocrine price target raised to $220 from $192 at Oppenheimer
- Soleno Therapeutics downgraded to Neutral from Outperform at Baird
- Soleno Therapeutics downgraded to Hold from Buy at Laidlaw
- Soleno Therapeutics rises 32.2%